340B Drug Pricing for RHCs: how to capture $80K-$200K/year of mandatory pharmacy savings
The federal program that requires drug manufacturers to discount outpatient drugs 30-50% for eligible RHCs and FQHCs. Most independent rural clinics in HPSA areas qualify but never register. Here's the practical playbook.
Frequently asked questions
What is the 340B Drug Pricing Program?
A federal program (established by §340B of the Public Health Service Act, 1992) requiring drug manufacturers to provide outpatient drugs to eligible health-care organizations at significantly discounted prices — typically 30-50% below the wholesale acquisition cost (WAC). Eligible "covered entities" include FQHCs, FQHC Look-Alikes, RHCs (selectively, since 2010 ACA), Critical Access Hospitals, disproportionate-share hospitals, Ryan White HIV/AIDS clinics, and several other federal-grant-recipient categories. Savings can fund expanded services for low-income patients but cannot duplicate the discount with Medicaid (the "no double dip" rule).
Are RHCs eligible for 340B?
Some are, some aren't. The 2010 Affordable Care Act extended 340B eligibility to RHCs that are "free-standing" (independently owned, not provider-based to a hospital) AND meet specific criteria for serving low-income or rural populations. Provider-based RHCs (owned by a hospital) inherit eligibility from the parent hospital. Most independent RHCs in HPSA-designated areas qualify; check eligibility via HRSA OPAIS (Office of Pharmacy Affairs Information System) lookup at opais.hrsa.gov.
How much does 340B save a typical RHC?
For a typical RHC with ~600 active Medicare patients and a moderate prescription volume: $80,000 - $200,000/year in drug-cost savings, captured by either (a) directly purchasing 340B-priced drugs for the in-house dispensary, OR (b) using a contract pharmacy network (most common) where the partner pharmacy fills prescriptions at retail and the savings flow back to the RHC via a per-prescription dispensing fee structure. Higher-volume practices (1,500+ patients with significant chronic-disease pharmacotherapy) can hit $400K-$700K/year.
What's a contract pharmacy network and why do I need one?
A contract pharmacy is a retail pharmacy (CVS, Walgreens, Walmart, regional independents) that contracts with your RHC to dispense 340B-priced drugs to your eligible patients. Most RHCs don't operate in-house pharmacies — the contract-pharmacy model lets you capture 340B savings without dispensing infrastructure. The RHC, the contract pharmacy, and a third-party administrator (TPA, often Apexus or RxStrategies) manage patient eligibility verification, claims tracking, and savings allocation. Pharma manufacturers have been narrowing contract-pharmacy access since 2020 — current state is fragmented; your TPA tracks which manufacturers ship to which contract pharmacies.
What are the most common 340B compliance gaps?
Five patterns dominate HRSA OPA audit findings: (1) duplicate discounts — billing Medicaid for a drug that was 340B-purchased without claiming the Medicaid 340B exclusion modifier; (2) ineligible patient dispensing — drugs dispensed to patients who weren't established with the RHC at the time of the prescription (the "patient definition"); (3) inadequate auditable records — RHCs that can't produce per-prescription evidence of patient eligibility, prescription origin, and savings calculation when audited; (4) replenishment-model errors — using the wrong drug National Drug Code (NDC) when restocking 340B inventory; (5) failure to file annual recertification by the deadline.
Does 340B interact with the new CMS 340B Medicare payment policy?
Yes. The 2024 D.C. Circuit ruling in American Hospital Association v. Becerra forced CMS to remediate hospitals for the 2018-2022 payment cuts to 340B drugs in the Medicare OPPS. The remediation policy began in CY2024 and continues through CY2026. For RHCs specifically, the impact is indirect — RHCs bill Medicare at the all-inclusive rate (AIR), not via OPPS, so the cuts and remediation primarily affected 340B-covered hospitals. RHCs benefit indirectly because the broader 340B program is more financially viable post-remediation, which improves contract-pharmacy economics.
Can I use 340B savings for any purpose?
No. HRSA guidance requires that 340B savings be used "to expand services, provide more comprehensive services, and improve services to patients." Most RHCs use savings to fund: care coordinators, behavioral-health staff, transportation services for low-income patients, sliding-fee dispensary stock, free clinic days, after-hours coverage. Savings cannot be diverted to general operating expenses unrelated to patient care.
How do I register for 340B?
Six steps: (1) confirm eligibility via OPAIS lookup at opais.hrsa.gov; (2) submit a 340B Eligibility Worksheet to HRSA OPA via OPAIS; (3) once approved, receive your 340B ID; (4) select a TPA (Apexus, RxStrategies, MicroMD-Onpharm, or similar) — most charge a per-prescription fee, typically $0.50-$2.00; (5) contract with retail pharmacies that participate in your TPA's network; (6) implement compliance procedures (dual-discount Medicaid carve-out, patient eligibility verification, audit-ready record keeping). Total timeline: 3-6 months from registration submission to first 340B prescription dispensed.
What's the duplicate-discount rule and how do I avoid it?
The "no double dip" rule: a 340B-purchased drug dispensed to a Medicaid patient cannot ALSO trigger a Medicaid drug rebate to the state Medicaid program (which would let the state collect a discount the manufacturer already gave you). To avoid this, RHCs must either (a) "carve out" Medicaid patients from 340B (don't dispense 340B drugs to Medicaid patients) OR (b) "carve in" with proper Medicaid claim modifiers (UD modifier on professional claims, NDC-level documentation on institutional). Most contract-pharmacy TPAs handle this automatically via their patient eligibility and claims-routing logic.
How does Triad Rev help with 340B?
Triad Rev surfaces 340B eligibility status from your HRSA OPAIS record, tracks per-prescription savings against the contract-pharmacy network if you connect your TPA report feed, flags potential duplicate-discount risk on Medicaid-billed claims, and generates the audit-ready savings-utilization report HRSA OPA requires for annual recertification. $499/mo, 90-day free pilot.